Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama.
The post Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug appeared first on MedCity News.
Related Articles
When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This
Meditech is integrating Suki’s AI assistant into more than a dozen rural...
FTC to sue PBMs over insulin pricing and rebates
From the FTC’s press release out today: Today, the Federal Trade Commission...
World Mental Health Day 2024
Every year, World Mental Health Day is an opportunity for mental health...
North Carolina’s Effort to Relieve Medical Debt
This policy watch examines the burden of medical debt in North Carolina...
Leave a comment